|
Risk level
|
Initiate therapy if:
|
Primary target LDL-C
|
Alternate target
|
|---|
|
High
|
• Consider treatment in all
|
• ≤2 mmol/L, or
|
• Apo B ≤0.8 g/L
|
|
FRS ≥20%
| |
• ≥50% ↓ in LDL-C
|
• Non HDL-C ≤2.6 mmol/L
|
|
Intermediate
|
• LDL-C ≥3.5 mmol/L
|
• ≤2 mmol/L,or
|
• Apo B ≤0.8 g/L
|
|
FRS = 10%-19%
|
• For LDL-C <3.5 consider if:
|
• ≥50% ↓ in LDL-C
|
• Non HDL-C ≤2.6 mmol/L
|
| |
→ Apo B ≥1.2 g/L, or
| | |
| |
→ Non-HDL-C ≥4.3 mmol/L
| | |
|
Low
|
• LDL-C ≥5.0 mmol/L
|
• ≥50% ↓ in LDL-C
| |
|
FRS <10%
|
• Familial hypercholesterolemia
| | |
- Adapted from Anderson et al., 2013 [125].
- FRS Framingham Risk Score, HDL-C high-density lipoprotein cholesterol, LDL-C, low-density lipoprotein cholesterol, apo B apolipoprotein B.
